The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions - PubMed
- ️Mon Jan 01 2018
The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions
Elizabeth M Nielson et al. Front Pharmacol. 2018.
Abstract
Research on the clinical applications of psychedelic-assisted psychotherapy has demonstrated promising early results for treatment of alcohol dependence. Detailed description of the content and methods of psychedelic-assisted psychotherapy, as it is conducted in clinical settings, is scarce. Methods: An open-label pilot (proof-of-concept) study of psilocybin-assisted treatment of alcohol dependence (NCT01534494) was conducted to generate data for a phase 2 RCT (NCT02061293) of a similar treatment in a larger population. The present paper presents a qualitative content analysis of the 17 debriefing sessions conducted in the pilot study, which occurred the day after corresponding psilocybin medication sessions. Results: Participants articulated a series of key phenomena related to change in drinking outcomes and acute subjective effects of psilocybin. Discussion: The data illuminate change processes in patients' own words during clinical sessions, shedding light on potential therapeutic mechanisms of change and how participants express effects of psilocybin. This study is unique in analyzing actual clinical sessions, as opposed to interviews of patients conducted separately from treatment.
Keywords: addiction treatment; alcoholism; ego-dissolution; hallucinogens; motivational interviewing; psilocybin; psychedelic assisted therapy; psychotherapy.
Similar articles
-
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Bogenschutz MP, et al. J Psychopharmacol. 2015 Mar;29(3):289-99. doi: 10.1177/0269881114565144. Epub 2015 Jan 13. J Psychopharmacol. 2015. PMID: 25586396 Clinical Trial.
-
Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L. Bogenschutz MP, et al. JAMA Psychiatry. 2022 Oct 1;79(10):953-962. doi: 10.1001/jamapsychiatry.2022.2096. JAMA Psychiatry. 2022. PMID: 36001306 Free PMC article.
-
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.
Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW. Noorani T, et al. J Psychopharmacol. 2018 Jul;32(7):756-769. doi: 10.1177/0269881118780612. Epub 2018 Jun 25. J Psychopharmacol. 2018. PMID: 29938565
-
Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy.
Horton DM, Morrison B, Schmidt J. Horton DM, et al. Am J Psychother. 2021 Dec 1;74(4):140-149. doi: 10.1176/appi.psychotherapy.20200055. Epub 2021 Jul 23. Am J Psychother. 2021. PMID: 34293927 Review.
-
Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.
Hendricks PS. Hendricks PS. Int Rev Psychiatry. 2018 Aug;30(4):331-342. doi: 10.1080/09540261.2018.1474185. Epub 2018 Sep 27. Int Rev Psychiatry. 2018. PMID: 30260256 Review.
Cited by
-
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.
Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, O'Keane V. Kelly JR, et al. Front Psychiatry. 2021 Dec 17;12:800072. doi: 10.3389/fpsyt.2021.800072. eCollection 2021. Front Psychiatry. 2021. PMID: 34975593 Free PMC article. Review.
-
Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, van den Brink W, Schoevers R. Breeksema JJ, et al. Sci Rep. 2024 Feb 5;14(1):2929. doi: 10.1038/s41598-024-53188-9. Sci Rep. 2024. PMID: 38316896 Free PMC article. Clinical Trial.
-
Wang J, Liang M, Shang Q, Qian H, An R, Liu H, Shao G, Li T, Liu X. Wang J, et al. CNS Neurosci Ther. 2023 Mar;29(3):831-841. doi: 10.1111/cns.14054. Epub 2023 Jan 10. CNS Neurosci Ther. 2023. PMID: 36627756 Free PMC article.
-
Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Breeksema JJ, et al. J Psychopharmacol. 2022 Oct;36(10):1100-1117. doi: 10.1177/02698811221116926. Epub 2022 Aug 26. J Psychopharmacol. 2022. PMID: 36017784 Free PMC article. Review.
-
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors.
Ponomarenko P, Seragnoli F, Calder A, Oehen P, Hasler G. Ponomarenko P, et al. J Psychopharmacol. 2023 Jul;37(7):660-678. doi: 10.1177/02698811231155117. Epub 2023 Feb 28. J Psychopharmacol. 2023. PMID: 36855289 Free PMC article.
References
-
- Atlas.ti (Version 7.0) (2004). [Qualitative Data Analysis]: Scientific Software Development GmbH. Available online at: www.atlasti.com
-
- Belser A. B., Agin-Liebes G., Swift T. C., Terrana S., Devenot N., Friedman H. L., et al. (2017). Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J. Human. Psychol. 57, 354–388. 10.1177/0022167817706884 - DOI
-
- Bogenschutz M. P., Forcehimes A. A. (2016). Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. J. Human. Psychol. 57, 389–414. 10.1177/0022167816673493 - DOI
LinkOut - more resources
Full Text Sources
Other Literature Sources